Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
about
Limitations of medical research and evidence at the patient-clinician encounter scaleThree simple rules to ensure reasonably credible subgroup analysesThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialPrediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort studyIndividualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposalA systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmedA comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerMultimorbidity and evidence generationMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerSubgroup analyses in confirmatory clinical trials: time to be specific about their purposesEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerCo-prescription trends in a large cohort of subjects predict substantial drug-drug interactionsSex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analysesClinical Prediction Models for Cardiovascular Disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model DatabaseHow well do randomized trials inform decision making: systematic review using comparative effectiveness research measures on acupuncture for back painRisk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data.Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings.Cardiovascular risk and statin use in the United StatesMoneyball, gambling, and the new cholesterol guidelines.Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trialsIndividual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.Tight glycemic control after pediatric cardiac surgery in high-risk patient populations: a secondary analysis of the safe pediatric euglycemia after cardiac surgery trialConceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized MedicineSeparating signal from noise: the challenge of identifying useful biomarkers in sepsis.Statistical analysis plan for the Stroke Oxygen Study (SO₂S): a multi-center randomized controlled trial to assess whether routine oxygen supplementation in the first 72 hours after a stroke improves long-term outcomeUsing evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much.Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.Predicting response to a cognitive-behavioral approach to treating low back pain: Secondary analysis of the BeST data set.Treatment matching for obesity: identifying mediators of psychosocial and behavioral intervention components.Individualized cost-effectiveness analysis.Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruitedDifferences between opioids: pharmacological, experimental, clinical and economical perspectivesIndividual differences and evidence-based psychopharmacologyBaseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerConceptual, methodological, and ethical problems in communicating uncertainty in clinical evidence.Random treatment assignment using mathematical equipoise for comparative effectiveness trials.Mixing nulliparous and multiparous women in randomised controlled trials of preeclampsia prevention is debatable: evidence from a systematic review.
P2860
Q24282606-082CCA7D-98D0-44A3-B48E-CE0E5F2B891CQ24289039-6B879FA2-DA39-4A0D-A6F8-FF7DABC14F43Q24595579-702D58D6-6446-4309-ACCD-0B9E36C8E1FAQ24658646-008EA7D4-C3D2-4EA9-8D30-48EBBF0506BCQ26739895-AC913A7C-883B-4843-A60F-B17F352C451BQ26862844-D6CE265A-2B81-4391-B14D-003CFB712368Q26865662-93BD2B1D-188F-4778-82BA-C0493A84BA36Q27014802-078590B7-F121-4909-92C2-2FB30F3F41F6Q27027648-70280164-8755-4EF6-B36A-8249DD33A545Q28067390-5DC5D409-4431-47B0-AA74-E2E4062EF5E9Q28084216-09CE0C8F-33B4-4C75-8DBF-C6B097949AF5Q28543801-1750330F-B171-49C1-A0A8-911AA79D9520Q28593306-08C1A662-04D8-4DF1-A06B-EC611BDD3525Q28646602-7A0D0C2D-A4C8-4F60-B037-C76DC43A2D8CQ31049424-19640D25-6B98-4127-8DC2-C6B38E502E05Q31112168-281D23FB-4130-4B55-A240-4D01A042FC81Q31119659-D111650D-846C-42BF-9D18-EB6105B954C7Q31143342-AA44D943-2EA6-4EE0-8A72-C9E2338F4BD4Q31160699-DB628777-A663-4A80-B21D-92B31E64F2F0Q33599663-08AFED62-F80C-43C3-AD96-AC4DC580DD5EQ33631548-E0B81813-22BD-437A-8C02-EF9E68190706Q33641217-3E4C270F-ABFD-4D82-9CD8-05CEC4833450Q33689688-6BEC52AA-9EEC-402F-9F27-14DA7E144E0EQ33707011-C0E90456-6344-465E-93BD-57251B582A36Q33714815-CB300941-7D71-4C05-98F2-DFC152D97F28Q33753941-F207D8D7-1228-44F2-B983-6AEDEB56FC33Q33792447-FE2B0403-1D41-4F6C-AB09-6490B95DF25BQ33830508-348ED97C-3951-4E4B-8EBE-3FEE2678552BQ33900204-03A9AB2C-951E-4703-8EE3-38B1548D7004Q33931900-D90E4467-2344-45C6-9628-49A27432609CQ33942569-6C6238C8-21BE-4580-9418-4DA9BFCCEFE3Q33963712-BA3ECA2F-8856-4571-B8C9-FB9CF64C7704Q34086851-C8685EB1-6592-4714-85A5-D3D80EC8B6A3Q34272502-F4B95F86-605A-49F0-94D2-D6E3976DD24BQ34422763-C3758D0B-71AC-4973-A3C1-41C27C37CC2DQ34506218-F36E8875-682F-4620-AE22-F84D2057039BQ34509675-6D52DEB3-41E8-49C3-82F3-9E02B22C64F6Q34547506-FEB0A865-BC78-4651-A80A-FD99BAA85A57Q34794180-D6C8A867-2DCE-457C-A9E0-6FB0EAFAE35DQ34795816-EFDECF10-6735-44DD-9803-22192254C724
P2860
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@ast
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en-gb
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@nl
type
label
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@ast
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en-gb
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@nl
prefLabel
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@ast
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en-gb
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@nl
P2093
P2860
P3181
P356
P1433
P1476
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
@en
P2093
David M Kent
Doug G Altman
Rodney A Hayward
P2860
P2888
P3181
P356
10.1186/1745-6215-11-85
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1045446161